What is HC Wainwright’s Forecast for ARQT FY2025 Earnings?

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) – Analysts at HC Wainwright raised their FY2025 earnings per share estimates for shares of Arcutis Biotherapeutics in a research note issued to investors on Wednesday, October 29th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of ($0.17) for the year, up from their prior forecast of ($0.49). HC Wainwright currently has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Arcutis Biotherapeutics’ current full-year earnings is ($1.33) per share. HC Wainwright also issued estimates for Arcutis Biotherapeutics’ Q4 2025 earnings at $0.10 EPS, Q1 2026 earnings at ($0.02) EPS, Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.10 EPS, FY2026 earnings at $0.43 EPS and FY2029 earnings at $2.82 EPS.

Several other equities analysts have also recently weighed in on the stock. Needham & Company LLC lifted their price objective on shares of Arcutis Biotherapeutics from $22.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday. Cowen reiterated a “buy” rating on shares of Arcutis Biotherapeutics in a report on Thursday, August 7th. The Goldman Sachs Group increased their price objective on Arcutis Biotherapeutics from $19.00 to $29.00 and gave the stock a “neutral” rating in a research note on Thursday. Mizuho set a $32.00 target price on Arcutis Biotherapeutics in a research note on Wednesday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Arcutis Biotherapeutics in a research report on Tuesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Arcutis Biotherapeutics presently has an average rating of “Moderate Buy” and an average price target of $28.00.

Arcutis Biotherapeutics Stock Up 1.6%

ARQT stock opened at $25.31 on Friday. The company has a debt-to-equity ratio of 0.68, a current ratio of 3.50 and a quick ratio of 3.04. The firm has a market capitalization of $3.10 billion, a P/E ratio of -70.31 and a beta of 2.06. Arcutis Biotherapeutics has a 52-week low of $8.21 and a 52-week high of $27.08. The company’s 50 day simple moving average is $18.92 and its 200-day simple moving average is $15.93.

Arcutis Biotherapeutics (NASDAQ:ARQT) last posted its quarterly earnings data on Tuesday, October 28th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.16. Arcutis Biotherapeutics had a negative net margin of 13.94% and a negative return on equity of 29.69%. The company had revenue of $99.22 million during the quarter, compared to analyst estimates of $86.69 million.

Insider Activity at Arcutis Biotherapeutics

In related news, insider Patrick Burnett sold 2,438 shares of the firm’s stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $15.57, for a total transaction of $37,959.66. Following the transaction, the insider owned 104,811 shares of the company’s stock, valued at approximately $1,631,907.27. This trade represents a 2.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Masaru Matsuda sold 36,130 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $16.16, for a total transaction of $583,860.80. Following the completion of the sale, the insider directly owned 161,234 shares of the company’s stock, valued at $2,605,541.44. This represents a 18.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 184,386 shares of company stock worth $3,498,387. 9.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Arcutis Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Perpetual Ltd raised its holdings in Arcutis Biotherapeutics by 7,534.3% during the third quarter. Perpetual Ltd now owns 2,024,606 shares of the company’s stock valued at $38,164,000 after buying an additional 1,998,086 shares in the last quarter. Paradigm Biocapital Advisors LP bought a new stake in shares of Arcutis Biotherapeutics during the 1st quarter worth about $22,918,000. Jennison Associates LLC increased its holdings in shares of Arcutis Biotherapeutics by 10.3% during the 3rd quarter. Jennison Associates LLC now owns 12,254,119 shares of the company’s stock valued at $230,990,000 after acquiring an additional 1,144,714 shares during the last quarter. Frazier Life Sciences Management L.P. increased its holdings in shares of Arcutis Biotherapeutics by 12.4% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 9,874,511 shares of the company’s stock valued at $138,441,000 after acquiring an additional 1,089,227 shares during the last quarter. Finally, Nuveen LLC bought a new position in shares of Arcutis Biotherapeutics in the 1st quarter valued at approximately $12,759,000.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.